ContraFect Corporation
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an inve… Read more
ContraFect Corporation (CFRXQ) - Total Liabilities
Latest total liabilities as of September 2023: $14.88 Million USD
Based on the latest financial reports, ContraFect Corporation (CFRXQ) has total liabilities worth $14.88 Million USD as of September 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ContraFect Corporation - Total Liabilities Trend (2016–2022)
This chart illustrates how ContraFect Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ContraFect Corporation Competitors by Total Liabilities
The table below lists competitors of ContraFect Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hinto Energy Inc
PINK:HENI
|
USA | $133.38K |
|
Marcventures Holdings Inc
PSE:MARC
|
Philippines | ₱1.10 Billion |
|
Sack Lunch Productions Inc
PINK:SAKL
|
USA | $2.02 Million |
|
CANADA RARE EARTH
BE:P4XA
|
Germany | €3.61 Million |
|
Energroup Holdings Corp
PINK:ENHD
|
USA | $7.37K |
Liability Composition Analysis (2016–2022)
This chart breaks down ContraFect Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ContraFect Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ContraFect Corporation (2016–2022)
The table below shows the annual total liabilities of ContraFect Corporation from 2016 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-09-30 | $32.53 Million | +87.11% |
| 2021-09-30 | $17.39 Million | -54.84% |
| 2020-09-30 | $38.50 Million | +97.78% |
| 2019-09-30 | $19.46 Million | -28.78% |
| 2018-09-30 | $27.33 Million | +43.88% |
| 2017-09-30 | $19.00 Million | +4.88% |
| 2016-09-30 | $18.11 Million | -- |